Hoffman Joins HepQuant as Clinical Lab Manager
Keith Hoffman Joins HepQuant as Clinical Lab Manager Brings more than 20 years of pharmaceutical industry experience in LC/MS analytics and lab management Keith Hoffman DENVER (Feb. 20, 2019) — HepQuant, LLC, a Greenwood Village, Colo.-based company with a unique, patented and patent-pending technology for evaluating the liver in patients…
First Patient Enrolled in a Pivotal Trial of the HepQuant SHUNT Liver Diagnostic Test
First Patient Enrolled in a Pivotal Trial of the HepQuant SHUNT Liver Diagnostic Test Study Aims to Enroll 420 Subjects in 20 U.S. Research Sites DENVER (Feb. 14, 2019) — HepQuant, LLC, a Greenwood Village, Colo.-based company with a unique, patented and patent-pending technology for evaluating the liver in patients…
Sarah Downing Joins HepQuant as Senior Manager of Quality Affairs
Sarah Downing Joins HepQuant as Senior Manager of Quality Affairs Certified Quality Engineer Brings More than 14 Years Experience in Medical Device and Diagnostics Quality Affairs Sarah Downing, Sr. Manager of Quality Affairs DENVER (Nov. 15, 2018) — HepQuant, LLC, a Greenwood Village, Colo.-based company with a unique, patented and patent-pending…
Receives IDE Approval from U.S. FDA to Initiate Clinical Trial of the SHUNT Liver Diagnostic Kit
HepQuant Receives IDE Approval from U.S. FDA to Initiate Clinical Trial of the SHUNT Liver Diagnostic Kit SAN FRANCISCO (Nov. 9, 2018) – While attending The Liver Meeting® 2018, HepQuant, LLC, a Greenwood Village, Colorado-based company with a unique, patented and patent-pending technology for evaluating the liver in patients with chronic…
Sean Bundy Appointed Director of Regulatory and Quality Affairs
HepQuant Appoints Sean Bundy Director of Regulatory & Quality Affairs Bringing 20 Years in Medical Device and Diagnostics Regulatory and Quality Experience DENVER (Aug. 2, 2018) — HepQuant, LLC, a Greenwood Village, Colo.-based company with a unique, patented and patent-pending technology for evaluating the liver in patients with chronic liver disease,…
HepQuant Chosen to Advance to InnoSTARS Semifinals in China
HepQuant Selected as a Semifinalist for 2018 InnoSTARS Competition to be Held in China DENVER (May 9, 2018) — HepQuant, LLC, a Greenwood Village, Colo.-based company with a unique, patented and patent-pending technology for evaluating the liver in patients with chronic liver disease, announced today that the company has been named…
HepQuant a Finalist for InnoSTARS Denver Competition
HepQuant a Finalist for 2018 InnoSTARS Denver Competition DENVER (April 24, 2018) — HepQuant, LLC, a Greenwood Village, Colo.-based company with a unique, patented and patent-pending technology for evaluating the liver in patients with chronic liver disease, announced today that the company has been named a finalist for the 2018 InnoSTARS Denver…
HepQuant and CTI Clinical Trial and Consulting Services Announce First Patient Enrolled in Liver Disease Diagnostic Trial
HepQuant and CTI Clinical Trial and Consulting Services Announce First Patient Enrolled in Liver Disease Diagnostic Trial FOR IMMEDIATE RELEASE [Covington, KY ~ January 25, 2018] HepQuant, LLC, a Greenwood Village, Colorado-based company with a unique, patented and patent-pending technology for evaluating the liver in patients with chronic liver disease…
HepQuant to Present Poster as Finalist at RESI San Francisco Innovation Challenge
HepQuant to Present Poster as a Finalist in the RESI San Francisco Innovation Challenge 2018 DENVER (January 2nd, 2017) — HepQuant, LLC, a Greenwood Village, Colorado-based company with a unique, patented and patent-pending technology for evaluating the liver in patients with chronic liver disease, today announced it will present a…
HepQuant to Present at the 10th Annual Biotech Showcase
HepQuant to Present at 10th Annual Biotech Showcase Senior Executives Will Also Attend the J.P. Morgan Healthcare Conference DENVER (December 13th, 2017) — HepQuant, LLC, a Greenwood Village, Colo.-based company with a unique, patented and patent-pending technology for evaluating the liver in patients with chronic liver disease, today announced it…